Eli Lilly office in San Francisco, US. Credits: Jennie Book/Shutterstock.

US pharma giant Eli Lilly plans to build a $2bn plant in western Germany, it has been reported.

The new plant would be Eli Lilly’s first major production complex in Germany.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Citing sources close the matter, Reuters reported that the site will make diabetes drugs and will create more than 1,000 jobs, including an expected boost in sub-contractors and regional suppliers.

“This is about a four-digit number of new employees,” one source is quoted as saying.

Eli Lilly declined to comment on the whereabouts of the new site for the plant, but a series of news conferences are scheduled to take place in the town of Alzey, 71km southwest of Frankfurt. The region in which Alzey is located is known for its wine-growing industry, the largest of the 13 designated wine regions in Germany.

Foreign direct investment (FDI) figures are on a downward trend in Germany, with net inflows reaching $11.05bn in 2022, down from a recent peak of $72.02bn in 2018, according to UNCTAD’s World Investment Report 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Several German cities, including Berlin, Munich and Düsseldorf, remain attractive FDI destinations for life science investors looking to bring supply chains closer to local markets.

In the pharma and healthcare sector, other businesses have similarly expressed their interest in investing in the country. In March, Switzerland-based La Roche introduced plans to build a $633.8m diagnostics production facility at its existing site in Penzberg. The new project will expand the current campus by 14ha and is expected to become operational by 2027.

Eli Lilly is headquartered in Indianapolis, US, and has more than 41,000 employees globally.